AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01390142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPer
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
Study NCT01390142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPer + IPost
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
Study NCT00184379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Structured disorder-related educational program for relatives
Study NCT02991586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Group of families
Study NCT03995342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin 15 grams after dissolution by mouth， every morning for three months.
Study NCT03995342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
Study NCT02682940 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vigilant Diabetes Management Application
Description: Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
Study NCT02409446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
Study NCT02365103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test meal I (given with water)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
Study NCT02365103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test meal II (simultaneously with tea)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
Study NCT02365103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test meal III (1 hour after test meal)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
Study NCT02365103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference iron dose
Description: 3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
Study NCT01898715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Study NCT04383951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary consult for participants in the ketogenic diet arm
Description: An initial consultation with the providers of medically supervised weight loss clinic will be arranged. Participants in the ketogenic diet group will be educated on the concepts of the diet and will be provided with recipes to be utilized at home that adhere to this diet. In addition to the initial consultation, participants in this arm receive additional consultations with these providers with a frequency as determined by the provider.
Study NCT04383951 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dietary consult for participants in the standard of care arm
Description: For participants in the standard of care arm, an initial consultation with the providers of medically supervised weight loss clinic will be arranged and the discussion will center around portion control using a balanced diet. Participants will receive only one additional consultation with the provider 16 weeks later just prior to the conclusion of the study.
Study NCT01078922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
Study NCT02271022 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT03190512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychological measurements
Description: Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
Study NCT03190512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological measurements
Description: Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
Study NCT02888379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Study NCT02888379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for TOP1288)
Study NCT03639727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid aerosol bronchial challenge
Description: Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
Study NCT03639727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol aerosol bronchial challenge
Description: Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
Study NCT00541905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
Study NCT02903303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypnosis
Description: It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning.
Study NCT04238533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eADAPT training
Description: eADAPT training for myoelectric prosthesis users is the comparator training.
Study NCT04238533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Conventional training with Myoboy has been the only training available to users.
Study NCT01774305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
Study NCT01774305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
Study NCT00136370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Study NCT00136370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Birth canal wipe
Study NCT00136370 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sterile water external genital wipe
Study NCT01408745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sternumfix
Description: sternotomy closure with Sternumfix
Study NCT01408745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steel wire
Description: sternotomy closure with steel wire
Study NCT00603083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine, Ketorolac and Adrenalin
Description: The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
Study NCT00603083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
Study NCT00953316 — intervention group
Intervention type: OTHER
Intervention: Measure infant's jaw, record all information about car seat testing, and administer questionnaires.
Description: Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
Study NCT03478137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP intervention
Description: Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
Study NCT01341847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water method colonoscopy
Description: This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
Study NCT01341847 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: air method colonoscopy
Description: This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
Study NCT02689453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 plus
Description: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
Study NCT02689453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
Study NCT02394249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity regime
Description: Information already included in arm descriptions
Study NCT03327831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Topical application followed by activation by ambient sunlight
Study NCT01807429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam
Description: Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
Study NCT01807429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 0.05 mg/kg
Study NCT00927901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 400 μg
Description: Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
Study NCT00927901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate 400 μg
Description: Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
Study NCT00927901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol xinafoate 400 μg
Description: Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
Study NCT02963519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VistaCare®
Study NCT02963519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressings
Study NCT00927901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
Study NCT01306006 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
Description: Normal measles vaccines licensed for distribution through the national EPI program
Study NCT03927183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: person-centred practice
Description: The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
Study NCT02802358 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)
Study NCT00546247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epofolate
Description: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
Study NCT01320878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost nebuliser solution
Description: iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
Study NCT01320878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost nebuliser solution
Description: iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
Study NCT01320878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: distilled water 2 ml per session
Study NCT00904709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
Study NCT01258647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caterpillar cereal
Description: A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
Study NCT03722511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Based Medical Food/Drink
Description: Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
Study NCT03521752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Exercise Program
Description: 4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
Study NCT03152487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celiac Plexus Neurolysis
Description: This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
Study NCT03152487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
Study NCT02437643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Participants will be prescribed hypo-caloric diet prescription.
Study NCT02437643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Participants will be prescribed hypo-caloric diet prescription.
Study NCT02437643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Protein
Description: Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
Study NCT01869140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal manual therapy
Description: spinal manipulation either manual or instrumental (activator)
Study NCT01869140 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: spinal manual therapy
Description: spinal manipulation either manual or instrumental (activator)
Study NCT03518242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT03518242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO
Study NCT03518242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03518242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection
Study NCT04751240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT and resistance training
Description: Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
Study NCT03226301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Venetoclax 15 cycles
Description: Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28
Study NCT03226301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib until progression/relapse
Description: 420mg ibrutinib daily until progression/relapse
Study NCT03226301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles
Description: Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28
Study NCT04373837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)
Description: The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.